Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acelyrin Inc
(NQ:
SLRN
)
6.510
-0.020 (-0.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
628,391
Open
6.550
Bid (Size)
6.210 (8)
Ask (Size)
6.910 (1)
Prev. Close
6.530
Today's Range
6.410 - 6.700
52wk Range
3.670 - 29.88
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 08, 2024
Via
Benzinga
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
June 05, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Performance
YTD
-18.01%
-18.01%
1 Month
+63.57%
+63.57%
3 Month
+35.06%
+35.06%
6 Month
-1.51%
-1.51%
1 Year
-71.93%
-71.93%
More News
Read More
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
May 15, 2024
Via
InvestorPlace
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
March 28, 2024
Via
InvestorPlace
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
May 29, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
May 09, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Announces Leadership Transition
May 09, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
April 29, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
March 28, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
March 27, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
March 20, 2024
Via
Benzinga
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
March 20, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
March 11, 2024
Via
Benzinga
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
March 11, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
March 11, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
February 15, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Acelyrin (SLRN) Investor Update: Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
January 16, 2024
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
SLRN DEADLINE TOMORROW: ROSEN, A LEADING NATIONAL FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
January 15, 2024
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
SLRN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
January 14, 2024
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
SLRN DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
January 13, 2024
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
ACELYRIN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Acelyrin, Inc. and Encourages Investors to Contact the Firm
January 12, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
SLRN IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action SLRN
January 12, 2024
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
SLRN DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors with Losses in Excess of $100k to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
January 11, 2024
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Acelyrin, and Beauty Health and Encourages Investors to Contact the Firm
January 10, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
